Compare Charles River Laboratories Intl. Inc (CRL) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs OneSpan Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while OneSpan Inc trades at $15.19 (market cap $574.63M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 19.4× OneSpan Inc's market cap, and OneSpan Inc pays a 3.35% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | OSPN | |
|---|---|---|
Market Cap | $11.14B | $574.63M |
Sector | Health | Technology |
52-Week High | $233.60 | $16.32 |
52-Week Low | $145.57 | $10.15 |
Enterprise Value | $14.00B | $532.83M |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
OneSpan (OSPN) trades at $15.09, down 0.53% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company demonstrates strong profitability with a net income margin of 28.47% and has beaten earnings estimates for the last three quarters. Recent news highlights investor attention and the upcoming Q2 2026 earnings release on August 4, 2026.
The outlook remains positive given consistent earnings beats and a 66.7% analyst buy rating, though the consensus price target of $13.50 suggests limited upside. Risks include negative net cash flow trends and potential margin compression, but strong ROE of 27.81% supports shareholder value. The stock presents a value opportunity with a P/E of 8.56, but investors should monitor execution against future guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
